Annexin Pharmaceuticals AB provided an update on its ongoing clinical study in patients with Retinal Vein Occlusion (RVO) using fluorescent labelled ANXV. Images in a case-report of a patient with RVO indicates site-specific accumulation of ANXV in the vessels affected by retinal vein occlusion. Annexin is collaborating with TRACER Europe BV ("TRACER") and the University Medical Center Groningen ("UMCG") on an innovative clinical molecular imaging trial.

The trial, also referred to as the SIGHT study, uses Annexin's fluorescently labelled drug candidate ANXV to visualize the effect of ANXV in patients with retinal vein occlusion (RVO). Recently, Dutch regulatory authorities also approved the inclusion of patients with diabetic retinopathy. ANXV holds the potential to rapidly improve retinal blood supply and reduce the risk of blindness and provide other short-term and long-term benefits in the acute setting in RVO, prior to the emergence of complications.

The SIGHT study is managed by TRACER, a CRO specializing in molecular imaging techniques and fast in-human clinical trials, and is sponsored by the UMCG, one of the largest hospitals in the Netherlands. The trial will include up to 16 patients is expected to be completed by the end of 2023. The results from the trial are expected to be a confirmation that ANXV reaches its target and may lead to refinement in selection of patients with RVO in future clinical trials.

ANXV has been found safe and tolerable in healthy volunteers in a Phase 1 study and is currently in Phase 2 clinical trial in the United States.